TCR2 Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch TCRR and buy or sell other stocks, options, and ETFs commission-free!

About TCRR

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. 

CEO
Garry E. Menzel, PhD, MBA
CEOGarry E. Menzel, PhD, MBA
Employees
Employees
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2015
Founded2015
Employees
Employees

TCRR Key Statistics

Market cap
58.08M
Market cap58.08M
Price-Earnings ratio
-0.35
Price-Earnings ratio-0.35
Dividend yield
Dividend yield
Average volume
694.31K
Average volume694.31K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$3.88
52 Week high$3.88
52 Week low
$0.821
52 Week low$0.821
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.